Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
5 Dow Stocks Poised to Beat on Earnings This Month
by Nalak Das
Despite severe market volatility, the Dow is still in positive territory with a gain of 15.9% year to date. This is an excellent performance after a disappointing 2018.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $85.04 in the latest trading session, marking a +0.41% move from the prior day.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View
by Zacks Equity Research
J&J (JNJ) comes up with encouraging third-quarter 2019 results.
Why Merck (MRK) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Seattle Genetics Up More Than 20% in 3 Months: Here's Why
by Zacks Equity Research
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
4 Stocks From Highest Job-Creating Sectors in September
by Zacks Equity Research
Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.
Top Ranked Growth Stocks to Buy for October 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, October 10th
J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case
by Zacks Equity Research
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
Merck (MRK) Stock Moves -1.33%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.27, moving -1.33% from the previous trading session.
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
by Zacks Equity Research
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
Novo Nordisk Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
Top Analyst Reports for General Dynamics, Merck & Progressive
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Merck & Co. (MRK) and Progressive (PGR).
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
by Kinjel Shah
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
by Zacks Equity Research
AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
Merck Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merck has been struggling lately, but the selling pressure may be coming to an end soon.
Merck (MRK) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data
by Zacks Equity Research
Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
Seattle Genetics Up on Positive Data From Bladder Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.